Moberg Pharma Past Earnings Performance
Past criteria checks 0/6
Moberg Pharma's earnings have been declining at an average annual rate of -34%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 88.3% per year.
Key information
-34.0%
Earnings growth rate
-16.4%
EPS growth rate
Pharmaceuticals Industry Growth | 30.5% |
Revenue growth rate | -88.3% |
Return on equity | -3.5% |
Net Margin | n/a |
Next Earnings Update | 07 May 2024 |
Revenue & Expenses BreakdownBeta
How Moberg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -21 | 25 | 4 |
30 Sep 23 | 0 | -18 | 23 | 3 |
30 Jun 23 | 0 | -16 | 22 | 2 |
31 Mar 23 | 0 | -16 | 22 | 1 |
31 Dec 22 | 0 | -16 | 21 | 1 |
30 Sep 22 | 0 | -17 | 20 | 2 |
30 Jun 22 | 0 | -16 | 19 | 2 |
31 Mar 22 | 0 | -16 | 18 | 3 |
31 Dec 21 | 0 | -16 | 19 | 3 |
30 Sep 21 | 34 | 8 | 21 | 5 |
30 Jun 21 | 34 | 7 | 21 | 6 |
31 Mar 21 | 34 | 5 | 22 | 6 |
31 Dec 20 | 34 | 7 | 22 | 6 |
30 Jun 20 | 50 | 20 | 24 | 7 |
30 Jun 19 | 31 | -8 | 31 | 13 |
31 Mar 19 | 455 | 31 | 269 | 18 |
31 Dec 18 | 5 | -28 | 26 | 13 |
30 Sep 18 | 341 | 9 | 217 | 16 |
30 Jun 18 | 340 | 19 | 210 | 15 |
31 Mar 18 | 334 | 6 | 206 | 14 |
31 Dec 17 | 439 | 11 | 261 | 14 |
30 Sep 17 | 438 | -1 | 268 | 15 |
30 Jun 17 | 434 | 0 | 253 | 15 |
31 Mar 17 | 369 | 35 | 218 | 13 |
31 Dec 16 | 334 | 33 | 201 | 12 |
30 Sep 16 | 299 | 36 | 181 | 15 |
30 Jun 16 | 261 | 32 | 168 | 15 |
31 Mar 16 | 282 | 9 | 165 | 19 |
31 Dec 15 | 286 | 26 | 159 | 23 |
30 Sep 15 | 276 | 25 | 158 | 22 |
30 Jun 15 | 260 | 20 | 150 | 25 |
31 Mar 15 | 226 | 19 | 130 | 23 |
31 Dec 14 | 200 | 12 | 120 | 20 |
30 Sep 14 | 193 | 12 | 112 | 20 |
30 Jun 14 | 179 | 4 | 110 | 21 |
31 Mar 14 | 167 | -5 | 111 | 25 |
31 Dec 13 | 157 | -11 | 104 | 29 |
30 Sep 13 | 151 | -17 | 91 | 31 |
30 Jun 13 | 140 | -11 | 76 | 32 |
Quality Earnings: MOB is currently unprofitable.
Growing Profit Margin: MOB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOB is unprofitable, and losses have increased over the past 5 years at a rate of 34% per year.
Accelerating Growth: Unable to compare MOB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: MOB has a negative Return on Equity (-3.45%), as it is currently unprofitable.